Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (CHD)

  • Stella Marie Reamon-Buettner1,
  • Si-Hyen Cho1 and
  • Juergen Borlak1Email author
BMC Medical Genetics20078:38

https://doi.org/10.1186/1471-2350-8-38

Received: 16 November 2006

Accepted: 25 June 2007

Published: 25 June 2007

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
16 Nov 2006 Submitted Original manuscript
22 Nov 2006 Reviewed Reviewer Report - Vidu Garg
7 Jan 2007 Reviewed Reviewer Report - Rumiko Matsuoka
26 Mar 2007 Reviewed Reviewer Report - Giuseppe Novelli
20 Apr 2007 Author responded Author comments - Juergen Borlak
Resubmission - Version 2
20 Apr 2007 Submitted Manuscript version 2
20 Apr 2007 Author responded Author comments - Juergen Borlak
Resubmission - Version 3
20 Apr 2007 Submitted Manuscript version 3
5 May 2007 Reviewed Reviewer Report - Giuseppe Novelli
8 Jun 2007 Reviewed Reviewer Report - Rumiko Matsuoka
16 Jun 2007 Author responded Author comments - Juergen Borlak
Resubmission - Version 4
16 Jun 2007 Submitted Manuscript version 4
Publishing
25 Jun 2007 Editorially accepted
25 Jun 2007 Article published 10.1186/1471-2350-8-38

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Drug Research and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine

Advertisement